trending Market Intelligence /marketintelligence/en/news-insights/trending/IoINxSDgDGaonD-0h5esOw2 content esgSubNav
In This List

Eisai insomnia drug Dayvigo wins US FDA approval

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Eisai insomnia drug Dayvigo wins US FDA approval

Eisai Co. Ltd. said the U.S. Food and Drug Administration approved its drug Dayvigo for treating insomnia in adults.

The Tokyo-based drugmaker said the U.S. regulator gave the nod to Dayvigo, or lemborexant, as a therapy for insomnia characterized by difficulties with sleep onset and maintenance. Insomnia is the most common sleep disorder, affecting 30% of the adult population globally.

Lemborexant works by acting on the orexin neurotransmitter system, which regulates a person's wakefulness. Eisai was previously collaborating with Purdue Pharma LP on the medicine, but the Japanese company took over sole development of the drug in May after the latter became embroiled in a series of lawsuits over the U.S. opioid epidemic.

Eisai's application for Dayvigo was based on the results of two phase 3 trials called Sunrise 1 and Sunrise 2, which enrolled about 2,000 patients.

Eisai is also seeking Japanese and Canadian approval for Dayvigo.